Mon–Thu 8am–4:30pm CT · Fri 8am–3pm CT
Clinical Trial · NCT06259123
Overview
Prospective single-center phase II study to evaluate the PSA, imaging and pathological response, as well as oncological outcomes of systemic radioligand therapy [177Lu]Lu-PSMAI&T (PSMA-RLT) in patients planned for radical prostatectomy (RP) for oligometastatic prostate cancer (PCa) diagnosed using [68Ga]Ga-PSMA-11 PET examination. Ten patients with oligometastatic primary PCa diagnosed using [68Ga]Ga-PSMA-11 PET-CT/MRI imaging will be included in this study.
Sponsor
Medical University of Vienna
Phase
Phase 2
Contacts
Sazan Rasul, PhD (Principal Investigator)
sazan.rasul@meduniwien.ac.at
004314040058742
Shahrokh F. Shariat, Professor
shahrokh.shariat@meduniwien.ac.at
004314040026150
ClinicalTrials.gov
NCT06259123Drug / Compound
Help us improve your experience